NEO (NeoGenomics) Total Equity: $828.8 Mil (As of Mar. 2026)


NEO NeoGenomics Inc NEO
71 GF Score
Price $14.17
GF Value $16.58
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Total Equity?

NeoGenomics NEO +3.32% 71 Total Equity is $828.8 Mil as of Mar. 2026. GuruFocus rates NEO with a GF Score™ of 71/100 and a GF Value™ of $16.58 (Modestly Undervalued). The stock has 6 warning signs investors should review.

NeoGenomics's total equity for the quarter that ended in Mar. 2026 was $828.8 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

NeoGenomics Total Equity Historical Data

* Premium members only.

The historical data trend for NeoGenomics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics Total Equity Chart

NeoGenomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,108.28 998.02 941.54 902.34 836.56

NeoGenomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 888.27 854.04 838.29 836.56 828.76
NEO
71GF Score
NeoGenomics Inc NEO
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeoGenomics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

NeoGenomics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1359.83-523.268
=836.6

NeoGenomics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=1346.531-517.771
=828.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $828.8 Mil mean?
NeoGenomics (NEO) has a Total Equity of $828.8 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for NeoGenomics and its competitors.
Is NeoGenomics' Total Equity too high?
NeoGenomics' current Total Equity is $828.8 Mil. Overall, NeoGenomics has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NeoGenomics' Total Equity compare to WGS and PSNL?
NeoGenomics' Total Equity of $828.8 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Diagnostics & Research company?
A good Total Equity depends on the Medical Diagnostics & Research industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for NeoGenomics and its competitors. NeoGenomics's current Total Equity is $828.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeoGenomics stock overvalued right now?
Based on GuruFocus' analysis, NeoGenomics (NEO) is currently considered Modestly Undervalued. The stock's GF Value™ is $16.58, compared to a current price of $14.17 — trading 14.5% below its estimated fair value. The current Total Equity is $828.8 Mil. NeoGenomics' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For NeoGenomics (NEO), the current Total Equity is $828.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeoGenomics (NEO) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued. The current stock price of $14.17 is trading 14.5% below its estimated GF Value™ of $16.58. GuruFocus considers NeoGenomics to be Modestly Undervalued.

Key valuation signals for NEO:

  • Total Equity: $828.8 Mil
  • GF Value™: $16.58 vs. price of $14.17 (14.5% below fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeoGenomics Business Description

Other Exchanges NEO:MexicoNG9:Germany
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
71GF Score

Get the complete analysis for NEO

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.17
Price
$16.58
GF Value